SCHEMBL25828642

SCHEMBL25828642

COc1ccccc1-c1n[nH]c2nccc(-c3ccc(N)cc3)c12

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FYN P06241 14/20 0.65
CHUK O15111 1/20 0.43
INSR P06213 1/20 0.43
MAPK8 P45983 1/20 0.43
CAMKK2 Q96RR4 1/20 0.43
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
GAA P10253 2/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30521921 0.86 FYN (0.66) FYNCHUKINSRMAPK8CAMKK2
SCHEMBL18613353 0.86 FYN (0.66) FYNCHUKINSRMAPK8CAMKK2
SCHEMBL30521658 0.85 FYN (0.68) FYNCHUKINSRMAPK8CAMKK2
SCHEMBL20485914 0.85 FYN (0.68) FYNCHUKINSRMAPK8CAMKK2
SCHEMBL18613447 0.85 FYN (0.67) FYNCHUKINSRMAPK8CAMKK2
SCHEMBL30521763 0.85 FYN (0.67) FYNCHUKINSRMAPK8CAMKK2
SCHEMBL30521837 0.84 FYN (0.64) FYNJAK2JAK3CCNB2CDK1
SCHEMBL18613515 0.84 FYN (0.64) FYNJAK2JAK3CCNB2CDK1
SCHEMBL30521893 0.84 FYN (0.66) FYNCHUKINSRMAPK8CAMKK2
SCHEMBL20485623 0.84 FYN (0.66) FYNCHUKINSRMAPK8CAMKK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors FYN, LCK, PTK2B FYN 1/4885CHUK 160/4885INSR 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.